DATA PAGE

2009: Turning the corner

Walter Yang

Despite the shaky start to 2009, the biotech sector regained its financial Although initial public offerings showed signs of resuscitation (at least footing. Biotech indices were up, as were offerings and partnership mon- 13 more companies are now in the queue), follow-on financings came in ies. Excluding collaborations, the sector raised a total of $24.3 billion. above $6 billion—the second-best year over the past decade.

• Stock market performance
• Global biotech industry financing

Although biotech indices were up ~16% last year, they underperformed The boost in partnership promises to US biotechs and follow-on financings

• other major indices.
• pushed industry funding to $61.3 billion, up 82% from 2008.

1,500

36.9 10.0 5.1 2.2 6.0 0.9

S&P 500
Swiss Market

2009 2008 2007 2006 2005 2004 2003

NASDAQ Biotech NASDAQ
Dow Jones

1,400 1,300 1,200 1,100 1,000
900

20.0 3.2 5.3 3.1 1.9 0.1
22.4 11.7 6.8 4.7 4.4 3.0

BioCentury 100

Partnering Debt and other Venture capital PIPEs

19.8 11.9 5.6 4.7 5.6 2.0
17.3 6.1 5.4 2.7 4.8 1.9
10.9 8.8 5.3 2.9 3.3 2.6
8.9 9.1 4.0 2.2 3.9 0.5

Follow-ons

800

IPOs

• 0
• 10
• 20
• 30
• 40
• 50
• 60
• 70

700

Amount raised ($ billions)

Partnership figures are for deals involving a US company. Source: BCIQ: BioCentury Online Intelligence, Burrill & Co.

Month ending

PIPEs, private investments in public equity; IPOs, initial public offerings

Global biotech venture capital (VC) investment
Global biotech initial public offerings (IPOs)

Venture money fell slightly last year, as private companies raised

• $5.1 billion versus $5.3 billion in 2008.
• The North American IPO market showed signs of life, with four companies

raising $705 million versus only one raising $6 million in 2008.

107

1,436

5,241

8,000
Asia-Pacific

Europe

585

1,055

1,309

58

1,206

4,315

3,500

7,000 6,000 5,000 4,000 3,000 2,000 1,000
0

78

1,451

3,871

69

1,213

4,045

55

1,145

4,070

Asia-Pacific Europe

53

1,130

3,947

230

474

1,852

3,000 2,500 2,000 1,500 1,000
500

40

797

Americas

98

869

1,063

15

930

913

Americas

3,151

65

158

705

43

19

483

12

115

6

• 2003
• 2004
• 2005
• 2006

Year

• 2007
• 2008
• 2009

0

• 2003
• 2004
• 2005
• 2006

Year

• 2007
• 2008
• 2009

• 2003 2004 2005
• 2006 2007 2008 2009

Americas Europe Asia-Pacific
184 77 5
190 82 6
182 95 9
204 81 8
223 105
9
212 101
6
196 87 4

2003 2004 2005 2006 2007 2008 2009
Americas Europe Asia-Pacific
815
35 12 6
18 24 3
26 21 3
23 21 7
132
433

Table indicates number of VC investments and includes rounds where the amount

• raised was not disclosed. Source: BCIQ: BioCentury Online Intelligence
• Table indicates number of IPOs. Source: BCIQ: BioCentury Online Intelligence

Notable 2009 deals

• IPOs
• Mergers and acquisitions

Percent change in stock price
($ millions) since offer completed
Target

Genentech Sepracor Medarex CV Therapeutics Cougar Biotechnology Ovation Pharmaceuticals Proteolix

Acquirer

Roche

• Value ($ millions)
• Date announced

Amount raised

• $46,800
• 12-Mar

Date

Dainippon Sumitomo Bristol-Myers Squibb Gilead Sciences Johnson & Johnson H. Lundbeck
$2,600 $2,400 $1,400 $1,000
$900
3-Sep 22-Jul 12-Mar 21-May 09-Feb 12-Oct

Company (lead underwriters)

Talecris (Morgan Stanley, Goldman Sachs, Citigroup, JPMorgan) Movetis (Credit Suisse, KBC) Cumberland (UBS, Jefferies, Wells Fargo) Omeros (Deutsche Bank)

• $550.0
• 17%
• 30-Sep

$146.0
$85.0 $68.2 $40.7
3%
–5%
–30% –13%
3-Dec 10-Aug 7-Oct

• Onyx Pharmaceuticals
• $851

• China Nuokang (Jefferies)
• 9-Dec

Licensing /collaboration Researcher Investor
Value
Venture capital

($ millions) Deal description

$1,924 Develop small molecules against four central nervous system disease targets

Amount raised
($ millions)

• PTC
• Roche

Round number Date closed

NA
Therapeutics

Company (lead investors)

• Nektar
• AstraZeneca $1,505 Worldwide rights to NKTR-118 for opioid-induced con-

stipation and NKTR-119 for pain without constipation
Clovis Oncology^a (Domain, New Enterprise Associates, Versant, Aberdare, Abingworth, Frazier, ProQuest, company management)

• $145.0
• 21-May

• Incyte
• Novartis
• $1,310 Ex-US rights to INCB18424; in phase 3 for myelofibro-

sis; worldwide rights to preclinical INCB28060

• Zogenix (Clarus, Domain)
• $71.0

$70.0 $68.0 $60.0 $56.4 $55.0
2653NA 3
07-Dec 10-Nov 12-Aug 30-Jun 12-May 18-Feb
Targacept Exelixis
AstraZeneca $1,240 Worldwide rights to develop and commercialize major depressive disorder compound TC-5214
Sanofiaventis
BioVex (Forbion, Morningside, Ventech, MVM) Pacific Biosciences^b (Deerfield, Intel) Hyperion (Bay City Capital, Panorama Capital) NovImmune (BZ Bank) Sopherion (Zoticon Bioventures)

^aLead investor not available. ^bSeries E extension.

>$1,161 Exclusive, worldwide rights to XL147 and XL765 in phase 1b/2 to treat cancer
ZymoGenetics Bristol-Myers $1,105 Codevelop and commercialize ZymoGenetics’ phase 1

Squibb

hepatitis C virus compound PEG-interferon lambda
>$1,075 Codevelop and commercialize therapeutics for obesity and related indications
Amylin Alder
Takeda Bristol-Myers $1,069 Worldwide rights to ALD518 for all indications, except

Squibb cancer

116

volume 28 number 2 february 2010 nature biotechnology